Added to Saved items
This page has been archived. It has not been updated since 24/12/2018. External links and references may no longer work.
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonyms: Leber's optic atrophy, Leber's hereditary optic atrophy, optic atrophy, Leber's optic neuropathy and hereditary optic neuroretinopathy

Leber's hereditary optic neuropathy (LHON) is a disease of mitochondria. There is usually 1 of 3 point mutations of DNA. These three are: G11778A, T14484C and G3460A. Clinical molecular genetic testing for these mutations is available. Overall, about 45 mutations have been discovered, (eg,  G10680A, T3394C) but these are much less common[1]. It may be inherited or, more rarely, a spontaneous mutation. Inheritance is entirely from the maternal side. This has sometimes led to the erroneous belief that it is an X-linked condition but inheritance is not Mendelian[2].

It seems likely that the aetiology is multifactorial. A complex interplay between genetic, hormonal and environmental factors may modulate the risk of a carrier losing vision[3]. Heavy smoking may be a significant risk factor.[4].

A study of North East England found that 11.8 per 100,000 had the LHON gene but the incidence of the disease was 3.22 per 100,000. The incidence of severe sight impairment due to LHON was 1 in 14,000[5]. A nationwide Japanese survey reported 120 cases of newly developed LHON during 2014, of whom 93.2% were males[6].

Mutation of the G11778A gene represents 60% of cases worldwide. There are 18 different phenotypes that have been assessed but 3 account for 95% of cases[2]. Up to 40% give no family history[7].

Penetrance is about 50-60% in males and 10-15% in females. Many, if not most, cases with no family history are due to incomplete penetrance rather than new mutation[2].

The mean age of onset is between 27 and 34 years with a range of 1 to 70 years.

  • It usually presents in young adults as painless subacute bilateral visual failure, affecting men more than women (3M:1F). Women tend to present a little later but the disease can be more severe.
  • It starts with blurring of central vision and desaturation of colour in both eyes simultaneously in about half of cases. If it is asymmetrical, both eyes are usually affected within 2-15 months.
  • The rate of progression can vary from rapid to over two years but most people are severely impaired by three or four months.
  • Central vision deteriorates to counting fingers in 80%. There may be temporary improvement before the atrophic phase.
  • Optic atrophy develops and clinical investigations are unhelpful in distinguishing it from other causes.
  • Visual acuity remains static thereafter. Most will be registered as severely sight impaired for the rest of their lives, with a permanent large scotoma.
  • Occasionally there is also dystonia and spasticity or a multiple sclerosis-like illness, especially in affected females.
  • A subgroup with onset in childhood has been identified in Italy[8].
  • Visual acuity is usually reduced to counting fingers.
  • Visual field testing shows an enlarging central scotoma.
  • Fluorescein angiography may be useful in the acute phase. The disc swells due to pseudo-oedema of the nerve fibre layer; peripapillary telangiectasias appear and there is increased tortuosity of the retinal vessels. Not everyone shows the full picture.
  • Electrophysiology studies, including pattern electroretinogram and visual evoked potentials, may demonstrate optic nerve dysfunction even without retinal disease.
  • CT scan or MRI scan of the brain is necessary to exclude other inflammatory and structural causes of an acute optic neuritis if there is no family history. MRI scan is often normal but may show a high signal within the optic nerves.
  • Biochemical mitochondrial studies may show respiratory chain defects[7].
  • There are many causes of acute bilateral visual failure that must be excluded during the acute phase, including tobacco amblyopia.
  • In the phase of optic atrophy, the inherited deafness-dystonia-optic neuropathy (Mohr-Tranebjaerg syndrome) must be considered[9].
  • Optic neuropathies can result in similar changes at the optic disc, particularly in late-stage disease, making it difficult to differentiate from glaucoma based on disc assessment alone[10].
  • Leber's congenital amaurosis (LCA) was described by the same doctor but is a different disease with several variants[11].

A number of studies have found associated conditions. The most common are cardiac pre-excitation syndromes, usually Wolff-Parkinson-White syndrome but also Lown-Ganong-Levine syndrome. A multiple sclerosis-like disease has also been described.

Currently, there is no value in monitoring asymptomatic people with the gene, as no effective prevention exists. However, clinical trials on gene therapy not only offer exciting possibilities for symptomatic patients, but also raise the prospect of prophylaxis in asymptomatic carriers[12].

Support, advice about jobs and visual aids will be required[13].

Some studies have reported a benefit from using the quinone analogue idebenone during the acute phase, although only a subgroup of patients experience clinically significant benefit. Studies suggest that it works at the level of the mitochondrial respiratory complexes[3].

It is noted that the optic neuropathy associated with vitamin B12 deficiency is very similar to Leber's congenital optic neuropathy and therefore some have advocated that known carriers of the gene defect should take care to have an adequate dietary intake of vitamin B12.

Mitochondrial replacement therapy is also being explored as a possible option[3].

The disease is inherited from the mother and not the father. An affected mother invariably passes on the gene although there is limited penetrance. De novo mutations are presumed rare and the 40% with no family history are largely accounted for by incomplete penetrance or failure to know the family. If the mother has the gene, so too will all siblings. It will be passed to all children by mothers and none by fathers. Genetic testing is not useful in predicting age of onset, severity, or rate of progression in asymptomatic carriers. Age and sex are important. An 18-year-old male has a lifetime risk of around 50% for developing the disease after a positive test result but this falls as years go by without manifestation. However, the risk never vanishes, as it can present late in life. If the mutation is heteroplasmic, it may not be present in every family member. Heteroplasmy occurs in 12%[5].

Intrauterine testing is not applicable, as no children of carrier fathers will be affected, although all children of carrier mothers will have the gene. However, it will be manifest in only 50% of male offspring and 15% of females with the risk of severe sight impairment being 40% and 10% respectively.

General wisdom holds that children who are at risk of a disorder that strikes in adulthood and for which there is no treatment, should not have testing unless there are symptoms. It is argued that asymptomatic testing removes the choice to know or not know this information, and it raises the possibility of stigma within the family and society, which could have serious implications for education and career. However, this strategy may change if gene therapy and mitochondrial replacement therapy fulfil their potential as a prophylactic treatment for asymptomatic patients.

  • In the acute phase, patients describe a loss of colour vision in one eye, followed by a painless subacute decrease in central visual acuity, accompanied by an enlarging central scotoma.
  • The second eye usually follows a similar course within three months, and significant improvements in visual acuity are rare for patients with G11778A or G3460A mutation. However, despite the severe visual impairment, some will gain some recovery of sight, particularly with the T14484C mutation.
  • In the chronic phase, patients usually have a bilateral visual deficit that is symmetrical and lifelong. Most remain legally severely sight impaired, are unable to drive a motor vehicle, and are unable to find employment.
  • It is hoped that the promising results obtained in studies of gene therapy in animal experiments and clinical trials in humans will translate into an improvement in the prognosis of this condition in the future[16].

Theodor Karl Gustav von Leber (pronounced LAY-ber) was born in 1840 and died in 1917[17]. He trained as a chemist but turned to medicine on the advice of Robert Bunsen of burner fame. He studied under Carl Ludwig and Albrecht von Graefe. He has lent his name to Franceschetti-Leber phenomenon, LCA, Leber's miliary aneurysm, Leber's plexus and LHON.

He described the disease in 1868 but little progress was made until the 1980s. Many different pedigrees have been described. Wallace and co-workers demonstrated that human mtDNA was maternally inherited and suggested that maternally transmitted diseases might be due to mtDNA mutations.

Further reading and references

  1. Iorga RE, Mihailovici R, Ozturk MR, et al; Leber's hereditary optic neuropathy - Case report. Rom J Ophthalmol. 2018 Jan-Mar62(1):64-71.

  2. Leber Optic Atrophy; Online Mendelian Inheritance in Man (OMIM)

  3. Jurkute N, Yu-Wai-Man P; Leber hereditary optic neuropathy: bridging the translational gap. Curr Opin Ophthalmol. 2017 Sep28(5):403-409. doi: 10.1097/ICU.0000000000000410.

  4. Dimitriadis K, Leonhardt M, Yu-Wai-Man P, et al; Leber's hereditary optic neuropathy with late disease onset: clinical and molecular characteristics of 20 patients. Orphanet J Rare Dis. 2014 Oct 239:158. doi: 10.1186/s13023-014-0158-9.

  5. Man PY, Griffiths PG, Brown DT, et al; The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003 Feb72(2):333-9. Epub 2002 Jan 7.

  6. Ueda K, Morizane Y, Shiraga F, et al; Nationwide epidemiological survey of Leber hereditary optic neuropathy in Japan. J Epidemiol. 2017 Sep27(9):447-450. doi: 10.1016/ Epub 2017 Apr 6.

  7. Yu-Wai-Man P, Chinnery PF; Leber Hereditary Optic Neuropathy

  8. Barboni P, Savini G, Valentino ML, et al; Leber's hereditary optic neuropathy with childhood onset. Invest Ophthalmol Vis Sci. 2006 Dec47(12):5303-9.

  9. Mohr-Tranebjaerg Syndrome, MTS; Online Mendelian Inheritance in Man (OMIM)

  10. O'Neill EC, Danesh-Meyer HV, Kong GX, et al; Optic disc evaluation in optic neuropathies: the optic disc assessment project. Ophthalmology. 2011 May118(5):964-70. doi: 10.1016/j.ophtha.2010.09.002. Epub 2010 Dec 3.

  11. Leber Congenital Amaurosis 1, LCA1; Online Mendelian Inheritance in Man (OMIM)

  12. Li B; Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months (LHON),, 2018.

  13. Iyer S; Novel therapeutic approaches for Leber's hereditary optic neuropathy. Discov Med. 2013 Mar15(82):141-9.

  14. Meyerson C, Van Stavern G, McClelland C; Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol. 2015 Jun 269:1165-76. doi: 10.2147/OPTH.S62021. eCollection 2015.

  15. Yu-Wai-Man P, Votruba M, Moore AT, et al; Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond). 2014 May28(5):521-37. doi: 10.1038/eye.2014.37. Epub 2014 Mar 7.

  16. Zhang Y, Tian Z, Yuan J, et al; The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy. Curr Gene Ther. 201717(4):320-326. doi: 10.2174/1566523218666171129204926.

  17. Theodor Karl Gustav von Leber;